REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY) today announced the completion of a Phase IIa clinical study in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia (CIN), a major side effect of myelosuppressive anti-cancer agents. “We are encouraged by these clinical data and FDA feedback on Maxygen’s proposed development plan for MAXY-G34 in CIN,” said Russell Howard, Maxygen’s Chief Executive Officer. “These events further confirm that, with the right partnership, a timely and cost effective development pathway to BLA filing can be achieved in 2013. MAXY-G34, with a product profile similar to Neulasta®, could be the 2nd entrant in the multi-billion dollar, long-acting G-CSF market.”
